Product Code: ETC051379 | Publication Date: Jul 2023 | Updated Date: Aug 2025 | Product Type: Report | |
Publisher: 6Wresearch | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 | |
The Saudi Arabia Gastrointestinal Drugs Market is expected to witness a CAGR of 8.6% during the forecast period 2025-2031. Rising prevalence of gastrointestinal diseases due to changing lifestyle and dietary habits is mainly driving the market growth in this region. Growing awareness among people regarding the treatment of GI diseases along with increasing healthcare expenditure are further propelling the overall market growth.
The rising prevalence rate of chronic gastrointestinal disorders such as Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), peptic ulcer disease, Crohn`s disease, diverticulitis, colorectal cancer, etc., has resulted into an increased demand for drugs used for their treatments have driven the growth of Saudi Arabia Gastrointestinal Drugs Market substantially over recent years. Developing Healthcare Infrastructure & Technology with growing number of hospitals and improved medical infrastructure also resulting in high adoption rates for advanced technologies like endoscopy and colonoscopy procedures; it will act as another major factor that can significantly boost up the demand for GI drugs in Saudi Arabia during forecast period. In order to improve healthcare sector development in Saudi Arabia government is implementing various supportive initiatives which include higher budget allocation towards health sector, implementation & acceptance Rx only medicines regulation by SFDA which encourages pharma companies to invest more into research & development activities resulting into launch new innovative products that lead to further propel its market growth throughout forecast period.
Many gastrointestinal drugs in Saudi Arabia are expensive and beyond the reach of many people, making it difficult for them to access treatments. Limited access to healthcare facilities: Although there is an increase in healthcare infrastructure over the past few years, most rural areas still lack adequate health services and medical facilities. This restricts access to diagnosis and treatment for gastrointestinal diseases.
The outbreak has caused a disruption in drug supply chains as well as decreased hospital visits due to fear of infection amongst patients suffering from gastroenterological conditions such as inflammatory bowel disease (IBD). Moreover, government initiatives focusing on Covid-19 have diverted resources away from other non-urgent health services resulting in delayed diagnoses and treatment for GI related issues during this period.
The key players operating in Saudi Arabia gastrointestinal drug market include Pfizer Inc., Sanofi S.A., AbbVie Inc., Johnson & Johnson Services Inc., Merck KGaA, Alvotech Manufacturing Ltd., Novartis AG, Boehringer Ingelheim GmbH etc.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Saudi Arabia Gastrointestinal Drugs Market Overview |
3.1 Saudi Arabia Country Macro Economic Indicators |
3.2 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 Saudi Arabia Gastrointestinal Drugs Market - Industry Life Cycle |
3.4 Saudi Arabia Gastrointestinal Drugs Market - Porter's Five Forces |
3.5 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume Share, By Drug Category, 2021 & 2031F |
3.6 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.7 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
3.8 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume Share, By Disease Types, 2021 & 2031F |
4 Saudi Arabia Gastrointestinal Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of gastrointestinal disorders in Saudi Arabia |
4.2.2 Growing awareness about gastrointestinal health and the importance of early diagnosis and treatment |
4.2.3 Rising healthcare expenditure in the country to improve healthcare infrastructure and access to advanced treatments |
4.3 Market Restraints |
4.3.1 Stringent regulations and approval processes for new gastrointestinal drugs in Saudi Arabia |
4.3.2 High cost associated with advanced gastrointestinal treatments and medications |
4.3.3 Limited availability of specialized healthcare professionals for gastrointestinal care in certain regions of the country |
5 Saudi Arabia Gastrointestinal Drugs Market Trends |
6 Saudi Arabia Gastrointestinal Drugs Market, By Types |
6.1 Saudi Arabia Gastrointestinal Drugs Market, By Drug Category |
6.1.1 Overview and Analysis |
6.1.2 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume, By Drug Category, 2021-2031F |
6.1.3 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume, By Antiemetic, 2021-2031F |
6.1.4 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume, By Acid Neutralizers, 2021-2031F |
6.1.5 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume, By Anti-inflammatory, 2021-2031F |
6.1.6 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume, By Laxatives & Antidiarrheal, 2021-2031F |
6.1.7 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume, By Others, 2021-2031F |
6.2 Saudi Arabia Gastrointestinal Drugs Market, By Route of Administration |
6.2.1 Overview and Analysis |
6.2.2 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume, By Oral, 2021-2031F |
6.2.3 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume, By Parenteral, 2021-2031F |
6.2.4 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume, By Rectal, 2021-2031F |
6.3 Saudi Arabia Gastrointestinal Drugs Market, By Distribution Channel |
6.3.1 Overview and Analysis |
6.3.2 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume, By Retail Pharmacies, 2021-2031F |
6.3.3 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume, By Online Pharmacies, 2021-2031F |
6.3.4 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume, By Hospital Pharmacies, 2021-2031F |
6.4 Saudi Arabia Gastrointestinal Drugs Market, By Disease Types |
6.4.1 Overview and Analysis |
6.4.2 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume, By Inflammatory Bowel Diseases, 2021-2031F |
6.4.3 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume, By Gastroesophageal Reflux Diseases, 2021-2031F |
6.4.4 Saudi Arabia Gastrointestinal Drugs Market Revenues & Volume, By Others, 2021-2031F |
7 Saudi Arabia Gastrointestinal Drugs Market Import-Export Trade Statistics |
7.1 Saudi Arabia Gastrointestinal Drugs Market Export to Major Countries |
7.2 Saudi Arabia Gastrointestinal Drugs Market Imports from Major Countries |
8 Saudi Arabia Gastrointestinal Drugs Market Key Performance Indicators |
8.1 Patient adherence rate to prescribed gastrointestinal medications |
8.2 Number of new product launches in the gastrointestinal drugs segment |
8.3 Rate of adoption of advanced diagnostic technologies for gastrointestinal disorders |
9 Saudi Arabia Gastrointestinal Drugs Market - Opportunity Assessment |
9.1 Saudi Arabia Gastrointestinal Drugs Market Opportunity Assessment, By Drug Category, 2021 & 2031F |
9.2 Saudi Arabia Gastrointestinal Drugs Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.3 Saudi Arabia Gastrointestinal Drugs Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
9.4 Saudi Arabia Gastrointestinal Drugs Market Opportunity Assessment, By Disease Types, 2021 & 2031F |
10 Saudi Arabia Gastrointestinal Drugs Market - Competitive Landscape |
10.1 Saudi Arabia Gastrointestinal Drugs Market Revenue Share, By Companies, 2024 |
10.2 Saudi Arabia Gastrointestinal Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |